The role of angiogenesis inhibitors in prostate cancer

Cancer Journal

Volumn 14, Issue 1, 2008, Pages 20-25

  Aragon Ching, Jeanny B ^a   Dahut, William L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Bevacizumab; Drugs; Prostate cancer; Thalidomide

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ABR 215050; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BICALUTAMIDE; CEDIRANIB; CELECOXIB; CILENGITIDE; DOCETAXEL; ENZASTAURIN; ESTRAMUSTINE; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; FUMAGILLOL CHLOROACETYLCARBAMATE; HYDROCORTISONE; KETOCONAZOLE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MITOXANTRONE; PAZOPANIB; PI 88; PREDNISONE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ROQUINIMEX; SEMAXANIB; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ZOLEDRONIC ACID; 4 ((4 FLUORO 2 METHYL 1H INDOL 5 YL)OXY) 6 METHOXY 7 (3 (PYRROLIDIN 1 YL)PROPOXY)QUINAZOLINE; 4-((4-FLUORO-2-METHYL-1H-INDOL-5-YL)OXY)-6-METHOXY-7-(3-(PYRROLIDIN-1-YL)PROPOXY)QUINAZOLINE; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANGIOGENESIS; ANOREXIA; BEDTIME DOSAGE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ADHESION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON PERFORATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DYSPHONIA; ENDOTHELIUM CELL; FATIGUE; FEBRILE NEUTROPENIA; HEART ARRHYTHMIA; HEMOLYSIS; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYNCOPE; THROMBOEMBOLISM; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VOMITING; MALE; NEOVASCULARIZATION (PATHOLOGY); PROSTATE TUMOR; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS; PYRIDINES; QUINAZOLINES; THALIDOMIDE;

EID: 43049178243     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318161c014     Document Type: Review

References (69)

1. Ries L, Krapcho M, Mariotto A, et al. SEER Cancer Statistics Review, 1975-2003, based on November 2005 SEER data submission. Available at: http://seer.cancer.gov/csr/1975-2003/. Accessed September 14, 2007.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
3. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177: 2106-2131.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
5. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
6. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972;175:409-416.
7. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med. 1975;82:96-100.
8. Srivastava A, Laidler P, Hughes LE, et al. Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. Eur J Cancer Clin Oncol. 1986;22:1205-1209.
9. Srivastava A, Laidler P, Davies RP, et al. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma: a quantitative histologic study. Am J Pathol. 1988;133:419-423.
10. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875-1887.
11. Macchiarini P, Fontanini G, Hardin MJ, et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet. 1992;340: 145-146.
12. Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
13. Jaeger TM, Weidner N, Chew K, et al. Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer J Urol. 1995; 154:69-71.
14. Weidner N, Carroll PR, Flax J, et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
15. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer. 1995;75:2545-2551.
16. Folkman J, Browder T, Palmblad J. Angiogenesis research: guidelines for translation to clinical application. Thromb Haemost. 2001;86:23-33.
17. Kerbel RS. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays. 1991; 13:31-36.
18. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 2005;65:671-680.
19. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58-62.
20. Epstein RJ. VEGF signaling inhibitors: More pro-apoptotic than antiangiogenic. Cancer Metastasis Rev. 2007;26:443-452.
21. Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem. 2007;7:1379-1393.
22. Zhao Q, Egashira K, Hiasa K, et al. Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury. Arterioscler Thromb Vasc Biol. 2004;24:2284-2289.
23. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs. 2007;16: 83-107.
24. Angiogenesis Inhibitors in Clinical Trials. Available at: http://www.cancer. gov/clinicaltrials/developments/anti-angio-table. Accessed September 14, 2007.
25. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
26. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997;64:971-978.
27. Kelsey FO. Thalidomide update: regulatory aspects. Teratology. 1988; 38:221-226.
28. Figg WD, Kruger EA, Price DK, et al. Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest New Drugs. 2002;20:183-194.
29. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1888-1893.
30. Figg WD, Arlen P, Gulley J, et al. A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen-independent prostate cancer. Semin Oncol. 2001;28:62-66.
31. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-2539.
32. Figg WD, Retter A, Steinberg SM, et al. In reply. J Clin Oncol. 2005;23:2113-2114.
33. Figg WD, Li H, Sissung T, et al. Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer. BJU Int. 2007;99:1047-1055.
34. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57:4593-4599.
35. Reese DM, Fratesi P, Corry M, et al. A phase II trial of humanized anti-vascular endothelial growth factor antibody for the treatment of androgen-independent prostate cancer. Prostate. 2001;3:65-70.
36. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006;24:250-253.
37. Picus J, Halabi S, Rini B, et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: initial results of CALGB 90006. Proc Am Soc Clin Oncol. 2003;22:1578.
38. Ning YM, Arlen P, Gulley J, et al. A phase II trial of thalidomide, bevacizumab, and docetaxel in patients (pts) with metastatic androgenindependent prostate cancer (AIPC). J Clin Oncol. 2007;25 (18 Suppl): 5114.
39. CALGB 90401: docetaxel and prednisone with or without bevacizumab in treating patients with prostate cancer that did not respond to hormone therapy. Available at: http://clinicaltrials.gov/ct/show/NCT00110214. Accessed September 22, 2007.
40. Tohnya TM, Ng SS, Dahut WL, et al. A phase I study of oral CC-5013 (lenalidomide, Revlimid), a thalidomide derivative, in patients with refractory metastatic cancer. Clin Prostate Cancer. 2004;2:241-243.
41. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
42. Aragon-Ching JB, Li H, Gardner E, et al. Thalidomide analogues as anticancer drugs. Rec Patents Anticancer Drug Discov. 2007;2:167-174.
43. Tohnya TM, Gulley J, Arlen PM, et al. Phase I study of lenalidomide, a novel thalidomide analog, in patients with refractory metastatic cancer. J Clin Oncol. 2006;24 (18 Suppl):13038.
44. Moss R, Mohile S, Shelton G, et al. A phase I open-label study using lenalidomide and docetaxel in androgen-independent prostate cancer (AIPC). Paper presented at: American Society for Clinical Oncology Prostate Cancer Symposium; February 22-24; Orlando, FL, 2007. Abstract 89.
45. NCT00348595: study of 2 different doses of revlimid in biochemically relapse prostate cancer. Available at: http://www.cancer.gov/search/ ViewClinicalTrials. aspx?cdrid=495215&version= HealthProfessional&protocolsearchid= 3676764Accessed September 22, 2007.
46. NCT00460031: phase II study of ketoconazole, hydrocortisone, and lenalidomide in patients with prostate cancer that progressed after androgen deprivation therapy. Available at: http://www.cancer.gov/search/ ViewClinicalTrials. aspx?cdrid=540496&version= HealthProfessional&protocolsearchid= 3676764. Assessed September 22, 2007.
47. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des. 2002;8:2255-2257.
48. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
49. Dahut WL, Scripture CD, Posadas EM, et al. Bony metastatic disease responses to sorafenib (BAY 43-9006) independent of PSA in patients with metastatic androgen independent prostate cancer. J Clin Oncol. 2006;24 (18 Suppl):4506.
50. Steinbild S, Mross K, Morant D, et al. Phase II study of sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: a study of the Central European Society for Anticancer Drug Research-EWIV (CESAR). J Clin Oncol. 2006;24 (18 Suppl):3094.
51. NCT00414388: sorafenib to overcome resistance to systemic chemotherapy in androgen-independent prostate cancer. Available at: http:// clinicaltrials.gov/show/NCT00414388. Accessed September 22, 2007.
52. Takeda M, Arao T, Yokote H, et al. AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor. Clin Cancer Res. 2007; 13:3051-3057.
53. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res. 2005; 65:4389-4400.
54. Drevs J, Siegert P, Medinger M, et al. Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2007;25:3045-3054.
55. Ryan CJ, Stadler WM, Roth B, et al. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007;25:445-451.
56. Vukanovic J, Isaacs JT. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 1995;55:1499-1504.
57. Vukanovic J, Hartley-Asp B, Isaacs JT. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate. 1995;26:235-246.
58. Shi J, Xiao Z, Ihnat MA, et al. Structure-activity relationships studies of the anti-angiogenic activities of linomide. Bioorg Med Chem Lett. 2003;13:1187-1189.
59. Isaacs JT, Pili R, Qian DZ, et al. Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate. 2006;66:1768-1778.
60. NCT00137436: study of SU011248 in combination with docetaxel (Taxotere) and prednisone in patients with prostate cancer. Available at: http://clinicaltrials.gov/show/NCT00137436. Accessed September 22, 2007.
61. Huss WJ, Barrios RJ, Greenberg NM. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol Cancer Ther. 2003;2:611-616.
62. Fong TA, Shawver LK, Sun L, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 1999;59:99-106.
63. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-896.
64. Kosmider O, Denis N, Dubreuil P, et al. Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene. 2007;26:3904-3908.
65. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol. 2007;25:1637-1638.
66. NCT00121238: phase II study of cilengitide in patients with nonmetastatic androgen-independent prostate cancer. Available at: http:// www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=438708& version=HealthProfessional&protocolsearchid=3680182.Accessed September 22, 2007.
67. Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther. 2006;5:22-27.
68. Logothetis CJ, Wu KK, Finn LD, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res. 2001;7:1198-1203.
69. NCT00268476: phase II/III randomized pilot study of androgen suppression (AS) alone versus AS in varying combinations with zoledronate, docetaxel, prednisolone, and/or celecoxib in patients with locally advanced or metastatic prostate cancer. Available at: http://clinicaltrials. gov/ct/show/NCT00268476. Accessed September 22, 2007.